Researchers found bedtime sublingual cyclobenzaprine reduced pain versus placebo and improved sleep, fatigue, and function with mostly mild oral adverse events.
A mid-stage trial for an experimental drug in ALS patients did not meet its main goal, with patients showing more gastrointestinal upset compared to a placebo, and differing death rates between groups. Results will be presented next year, and a long-term extension study will continue.